Research Article
The Management of Patients after Surgical Treatment of Maxillofacial Tumors
Table 1
Baseline characteristics.
| | % () | |
| Age | 12–93 years | 58.36 ± 7.56 |
| Gender | | | Female | 44.33 (219/494) | | Male | 55.67 (275/494) | |
| Postoperative loss | | | Group I | 44.75 (226/495) | | Bone loss1 | 92.03 (208/226) | | Class I | 41.83 (87/208) | | Class II | 27.41 (57/208) | | Class III | 6.73 (14/208) | | Class IV | 8.17 (17/208) | | Class V | 2.88 (6/208) | | Class VI | 12.98 (27/208) | | Group II | 47.37 (234/494) | | Bone loss2 | 69.23 (162/234) | | Class A | 40.12 (65/162) | | A1 | 40.00 (26/65) | | A2 | 46.15 (30/65) | | A3 | 13.85 (9/65) | | Class B | 27.16 (44/162) | | B1 | 9.09 (4/44) | | B2 | 75.00 (33/44) | | B3 | 15.91 (7/44) | | Class C | 32.72 (53/162) | | C1 | 94.34 (50/53) | | C2 | 5.66 (3/53) | | C3 | 0.00 (0/53) | | Group III | 3.44 (17/494) | | Group IV | 3.44 (17/494) | |
| Supplementary treatment | 69.63 (344/494) | | Radiotherapy | 85.47 (294/344) | | Chemotherapy | 4.65 (16/344) | | Radio- and chemotherapy | 9.88 (34/344) | |
| Cause of surgical treatment | | | Squamous carcinoma | 66.40 (328/494) | | Ameloblastoma | 3.24 (16/494) | | Tumor mixtus | 2.43 (12/494) | | Adenocarcinoma | 2.02 (10/494) | | Other | 25.91 (128/494) | |
|
|
Aramany’s classification; 2Furuta classification.
|